Salbutamol

English name albuterol

also known as albuterol · albuterol sulfate · Ventolin · Salbutamol sulfate · PROAIR HFA · Salbutamol sulphate · A006 · Albuterol Spiromax · +44 more

Developed for: asthma · chronic obstructive pulmonary disease · exercise-induced bronchoconstriction · bronchiolitis · childhood onset asthma · acute asthma · cystic fibrosis · obstructive lung disease
+44 more
· lung disorder · respiratory syncytial virus bronchiolitis · status asthmaticus · acute bronchiolitis · acute lung injury · acute respiratory failure · amyotrophic lateral sclerosis · bronchial disorder · bronchitis · bronchopulmonary dysplasia · congenital myasthenic syndrome · congestive heart failure · facioscapulohumeral muscular dystrophy · food allergy · generalized myasthenia gravis · glycogen storage disease due to acid maltase deficiency, infantile onset · glycogen storage disease due to acid maltase deficiency, late-onset · glycogen storage disease II · isoproterenol-mediated vasodilatation · left ventricular failure · lymphangioleiomyomatosis · mucus inspissation of respiratory tract · multiple sclerosis · muscular dystrophy, scapulohumeral · organophosphate poisoning · persistent tachypnoe of infancy, usual · pulmonary arterial hypertension · pulmonary edema · pulmonary hypertension · respiratory failure · spinal cord injury · upper limb hypertrophy · urinary tract obstruction · ventricular septal defect · adult acute respiratory distress syndrome · allergic asthma · cardiomyopathy · congenital myopathy · heart failure · idiopathic pulmonary arterial hypertension · myopathy · pulmonary hypertension, neonatal · reactive airway disease · Riley-Day syndrome
Investigated by: Teva Branded Pharmaceutical Products R&D, Inc. · AstraZeneca · Boehringer Ingelheim · GlaxoSmithKline · Amphastar Pharmaceuticals, Inc. · National Heart, Lung, and Blood Institute (NHLBI)
+149 more
· Assistance Publique - Hôpitaux de Paris · Duke University · Hadassah Medical Organization · Parexel · Sumitomo Pharma America, Inc. · University of California, San Francisco · University of Copenhagen · Aerogen · Assiut University · Bond Avillion 2 Development LP · Chiesi Farmaceutici S.p.A. · Concentrx Pharmaceuticals, Inc. · Fraunhofer-Institute of Toxicology and Experimental Medicine · Henan University of Traditional Chinese Medicine · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy · Kramer Consulting, LLC · Laval University · Mayo Clinic · Mylan Pharmaceuticals Inc · Nemours Children's Clinic · Ohio State University · Pennington Biomedical Research Center · PharPoint Research, Inc. · Rambam Health Care Campus · University Hospital, Tours · University of Aarhus · University of Arizona · University of British Columbia · University of Miami · Vanderbilt University Medical Center · Acerus Pharmaceuticals Corporation · American College of Clinical Pharmacy · Armed Forces Hospital, Pakistan · Australian Lung Health Initiative Pty Ltd · Autoimmunity Centers of Excellence · Beijing Chao Yang Hospital · Bispebjerg Hospital · California Transplant Donor Network · Cambridge University Hospitals NHS Foundation Trust · Caring Friends, Mumbai · Central Hospital, Nancy, France · Chang Gung Memorial Hospital · Chang Gung University · Children's Hospital Los Angeles · Chongqing Medical University · Cipla Ltd. · Clinical Trial Unit, University Hospital Basel, Switzerland · Clínica Vespucio, Santiago, Chile · Conselho Nacional de Desenvolvimento Científico e Tecnológico · Dey · Dr. J. Alberto Neder · ETH Zurich (Switzerland) · Eli Lilly and Company · Erasmus Medical Center · FDA Office of Orphan Products Development · Federal University of Rio Grande do Norte · First Affiliated Hospital Xi'an Jiaotong University · First Affiliated Hospital of Chongqing Medical University · Flight Attendant Medical Research Institute · Fortrea · Guangzhou Panyu Central Hospital · Hamilton Health Sciences Corporation · Helsinki University Central Hospital · Hospital Infantil de Mexico Federico Gomez · IRCCS Azienda Ospedaliero-Universitaria di Bologna · Ibirapuera University · Imperial College London · Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Intech Biopharm Ltd. · Johns Hopkins University · Jordan University of Science and Technology · Kern Medical Center · Khyber Teaching Hospital · King Abdullah University Hospital · all 155 on the full record

Regulatory milestones approvals, filings & regulatory actions · 15 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	PROAIR RESPICLICK	—	2016-04-28	fda.gov ↗
Filed	US (FDA)	ProAir® RespiClick	asthma, exercise-induced bronchoconstriction	2015-09-10	“the U.S. Food and Drug Administration (FDA) has accepted for review the company’s supplemental new drug application (sNDA) for ProAir® RespiClick (albuterol sulfate) Inhalation Powder” tevapharm.com ↗
Filed	US (FDA)	—	asthma, exercise-induced bronchoconstriction	2014-07-14	“the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug application (NDA) for albuterol multi-dose dry-powder inhaler (MDPI)” tevapharm.com ↗
Label expansions (2)	US (FDA)	PROAIR HFA	—	2006-02-03 – 2008-09-16	fda.gov ↗
Label expansion	US (FDA)	VENTOLIN HFA	—	2008-03-26	fda.gov ↗
Label expansions (2)	US (FDA)	PROVENTIL-HFA	—	1998-09-23 – 1999-06-02	fda.gov ↗
Label expansions (3)	US (FDA)	PROVENTIL	—	1984-09-13 – 1997-09-18	fda.gov ↗
Label expansions (3)	US (FDA)	VENTOLIN	—	1990-09-24 – 1997-06-16	fda.gov ↗
Approved	US (FDA)	VENTOLIN	—	1981-05-01	fda.gov ↗

Trials 198 · started per year

today

US approved 1981

1980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 05 trials
Phase 0	NCT07591558	Jun → Oct 2026 expected	diabetes mellitus, lung disorder	King Abdullah University Hospital	Not yet recruiting	No outcome recorded
Phase 0	NCT06319183	Mar → Jun 2024	—	Tongji University	Unknown	No outcome recorded
Phase 0	NCT06139029	Nov 2022 → Mar 2023	acute bronchiolitis	Mardan Medical Complex	Completed	No outcome recorded
Phase 0	NCT03889379	Jan 2019 → Jun 2021	—	University of Arizona	Withdrawn	No outcome recorded
Phase 0	NCT02135965	Apr 2009 → Aug 2011	—	Pennington Biomedical Research Center	Completed	No outcome recorded
Phase 129 trials
Phase 1	NCT06514157	Aug → Sep 2024	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT06433921	Aug 2024 → Feb 2027 expected	asthma	GlaxoSmithKline	Recruiting	No outcome recorded
Phase 1	NCT06921291	Aug → Dec 2024	—	Khyber Teaching Hospital	Completed	No outcome recorded
Phase 1	NCT06433908	Jun → Oct 2024	asthma	GlaxoSmithKline	Completed	Mixed
Phase 1	NCT06290102	May → Oct 2024	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 1	NCT06271408	Feb → Apr 2024	chronic obstructive pulmonary disease	Polarean, Inc.	Unknown	No outcome recorded
Phase 1	NCT06027606	Sep 2023 → Sep 2025	—	University of Alberta	Completed	No outcome recorded
Phase 1	NCT05791565	Apr → May 2023	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT03436225	Feb 2019	respiratory syncytial virus bronchiolitis	Assiut University	Unknown	No outcome recorded
Phase 1	NCT03772223	Jan → May 2019	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT03514615	Jan → Jul 2018	—	University Hospitals, Leicester	Completed	No outcome recorded
Phase 1	NCT03373409	Nov 2017 → May 2018	asthma	Concentrx Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT03098680	Apr 2017 → Feb 2020	cardiovascular disorder	Cambridge University Hospitals NHS Foundation Trust	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT03480997	Dec 2016 → Apr 2017	chronic obstructive pulmonary disease	Pneuma Respiratory, Inc	Completed	No outcome recorded
Phase 1	NCT02566252	Jul 2015 → Jan 2016	—	Pulmotect, Inc.	Completed	No outcome recorded
Phase 1	NCT01984086	Oct 2013 → May 2014	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01895998	Aug 2013 → Apr 2014	sickle cell disease	Duke University	Completed	No outcome recorded
Phase 1	NCT01844401	Apr → Aug 2013	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 1	NCT01859624	Jun 2012 → Apr 2013	glycogen storage disease due to acid maltase deficiency, late-onset	Duke University	Completed	No outcome recorded
Phase 1	NCT01457261	Apr 2012 → Nov 2014	idiopathic pulmonary fibrosis	Royal Brompton & Harefield NHS Foundation Trust	Completed	No outcome recorded
Phase 1	NCT01263197	Dec 2010 → Mar 2011	major depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT01203592	Sep 2010 → Aug 2013	congenital myasthenic syndrome	Mayo Clinic	Completed	No outcome recorded
Phase 1	NCT02207452	Aug 2010 → Jul 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01056159	Jan → Jun 2010	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 1	NCT00674050	May → Sep 2008	diabetes mellitus	Mannkind Corporation	Completed	No outcome recorded
Phase 1	NCT00549120	Aug → Oct 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00649779	Sep → Oct 2005	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT00649987	Sep → Oct 2005	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT02173678	Oct → Nov 1999	—	Boehringer Ingelheim	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT01799538	Jun 2013 → Nov 2027 expected	lymphangioleiomyomatosis	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	No outcome recorded
Phase 1/2	NCT01885936	Jun 2013 → Dec 2016	glycogen storage disease II	Duke University	Completed	No outcome recorded
Phase 222 trials · 4 met primary · 1 missed
Phase 2	NCT06644924	Feb → Jun 2025	asthma	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT05860244	Sep 2024 → Jul 2025	amyotrophic lateral sclerosis	Assistance Publique - Hôpitaux de Paris	Unknown	No outcome recorded
Phase 2	NCT03643874	Jun → Aug 2018	asthma	Concentrx Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT03371459	Dec 2017 → Mar 2018	asthma	AstraZeneca	Completed	Met primary
Phase 2	NCT03364608	Dec 2017 → Mar 2018	asthma	AstraZeneca	Completed	Met primary
Phase 2	NCT03270332	Oct 2017 → Jul 2020	pulmonary hypertension	University of Miami	Completed	No outcome recorded
Phase 2	NCT02542254	Oct → Dec 2015	chronic obstructive pulmonary disease	Verona Pharma, Inc.	Completed	No outcome recorded
Phase 2	NCT01957293	Oct 2013 → Jan 2014	—	University of Basel	Completed	No outcome recorded
Phase 2	NCT01252758	Nov 2012 → Apr 2013	asthma	Acerus Pharmaceuticals Corporation	Withdrawn	No outcome recorded
Phase 2	NCT01581177	Apr → Jul 2012	asthma	Amphastar Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT01958814	Feb 2012 → Jul 2015	respiratory failure	University Hospital, Tours	Completed	No outcome recorded
Phase 2	NCT01470755	Jan 2012 → Jan 2014	asthma	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT01174732	Jul → Oct 2010	asthma	Amphastar Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT01189396	Jul → Dec 2010	asthma, chronic obstructive pulmonary disease	Amphastar Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT01058863	Feb → Jun 2010	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	Met primary
Phase 2	NCT00818454	Dec 2008 → Sep 2009	asthma	Boehringer Ingelheim	Completed	Met primary
Phase 2	NCT00696540	Jun → Sep 2008	bronchiolitis	University Diego Portales	Unknown	No outcome recorded
Phase 2	NCT00310401	Apr 2007 → May 2011	pulmonary edema	Vanderbilt University Medical Center	Completed	Missed primary
Phase 2	NCT00320034	Apr 2006 → Jun 2008	asthma	Hamilton Health Sciences Corporation	Completed	No outcome recorded
Phase 2	NCT00358488	Apr 2006 → Jan 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00096616	Nov 2004 → Mar 2006	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02182674	Oct 2000 → Aug 2001	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded

Phase 2/34 trials
Phase 2/3	NCT06815679	Mar 2025 → Jan 2026 overdue	acute respiratory failure, pneumonia	Università degli Studi di Ferrara	Not yet recruiting	No outcome recorded
Phase 2/3	NCT03914638	Apr 2019 → Oct 2021	generalized myasthenia gravis	University of Aarhus	Unknown	No outcome recorded
Phase 2/3	NCT01375361	Apr 2009 → Jul 2010	congestive heart failure	University of California, San Francisco	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2/3	NCT00755079	Apr 2007 → Aug 2012	spinal cord injury	US Department of Veterans Affairs	Completed	No outcome recorded
Phase 347 trials · 13 met primary
Phase 3	NCT06664619	Dec 2024 → Nov 2026 expected	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Active not recruiting	No outcome recorded
Phase 3	NCT06261957	May 2024 → Sep 2025	asthma	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT06307665	May 2024 → Oct 2027 expected	asthma	AstraZeneca	Recruiting	No outcome recorded
Phase 3	NCT06245551	Dec 2023 → Jun 2024	exercise-induced bronchoconstriction	AstraZeneca	Completed	Met primary
Phase 3	NCT06154304	Dec 2023 → Sep 2024	asthma	Cipla Ltd.	Completed	No outcome recorded
Phase 3	NCT05653024	Jul 2023 → May 2025	food allergy	Philippe Bégin	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT05505734	Sep 2022 → Aug 2024	asthma	Bond Avillion 2 Development LP	Completed	Met primary
Phase 3	NCT06946264	Jul 2022 → Dec 2029 expected	bronchiolitis	Nemours Children's Clinic	Recruiting	No outcome recorded
Phase 3	NCT04234464	Jan → Aug 2020	exercise-induced bronchoconstriction	Bond Avillion 2 Development LP	Completed	Met primary
Phase 3	NCT03449056	Jan 2019 → Jan 2020	chronic obstructive pulmonary disease	Poitiers University Hospital	Unknown	No outcome recorded
Phase 3	NCT03528577	Sep 2018 → Mar 2019	asthma	Sun Pharmaceutical Industries, Inc.	Completed	No outcome recorded
Phase 3	NCT03816267	May 2018 → Mar 2019	asthma	Suez Canal University	Completed	No outcome recorded
Phase 3	NCT03256695	Sep 2017 → Apr 2018	chronic obstructive pulmonary disease	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT03169504	May 2017 → May 2018	chronic obstructive pulmonary disease	Henan University of Traditional Chinese Medicine	Unknown	Mixed
Phase 3	NCT02969408	Feb 2017 → Feb 2018	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT03208894	Nov 2016 → May 2017	persistent tachypnoe of infancy, usual	Armed Forces Hospital, Pakistan	Completed	No outcome recorded
Phase 3	NCT02885636	Sep 2016 → Sep 2017	left ventricular failure	Mayo Clinic	Completed	Met primary
Phase 3	NCT02782052	Jul 2016 → Oct 2018	pulmonary arterial hypertension	Assistance Publique - Hôpitaux de Paris	Withdrawn	No outcome recorded
Phase 3	NCT02160548	Apr → Dec 2015	organophosphate poisoning	Sylhet M.A.G.Osmani Medical College	Completed	No outcome recorded
Phase 3	NCT02126839	May 2014 → Feb 2015	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	Met primary
Phase 3	NCT01857323	May → Aug 2013	asthma, chronic obstructive pulmonary disease	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT01836016	May 2013 → May 2015	chronic obstructive pulmonary disease	Henan University of Traditional Chinese Medicine	Unknown	No outcome recorded
Phase 3	NCT01791972	Mar → May 2013	exercise-induced bronchoconstriction	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	Met primary
Phase 3	NCT01747629	Dec 2012 → Oct 2013	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	Met primary
Phase 3	NCT01424813	Dec 2012 → Oct 2013	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	Met primary
Phase 3	NCT01698320	Oct 2012 → Dec 2013	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT01218009	Oct → Dec 2010	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Terminated	No outcome recorded
Phase 3	NCT01096017	Mar → Apr 2010	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT01076322	Mar 2009 → Jun 2010	asthma	Taiwan Otsuka Pharm. Co., Ltd	Completed	No outcome recorded
Phase 3	NCT00669617	Apr → Aug 2008	chronic obstructive pulmonary disease	Novartis	Completed	No outcome recorded
Phase 3	NCT00634517	Mar → Dec 2008	asthma	Amphastar Pharmaceuticals, Inc.	Terminated	No outcome recorded
Phase 3	NCT00634829	Feb → Oct 2008	exercise-induced bronchoconstriction	Amphastar Pharmaceuticals, Inc.	Terminated	No outcome recorded
Phase 3	NCT00528723	Nov 2007 → Jan 2009	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT00635505	Sep 2007 → Aug 2008	asthma	Amphastar Pharmaceuticals, Inc.	Terminated	No outcome recorded
Phase 3	NCT00577655	Aug 2007 → Jul 2008	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT00990847	Jun 2007 → Apr 2008	acute asthma	PT Otsuka Indonesia	Completed	No outcome recorded
Phase 3	NCT00462540	May → Sep 2007	chronic obstructive pulmonary disease	Dey	Completed	Met primary
Phase 3	NCT00400153	Nov 2006 → Apr 2008	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT00308685	Jun → Dec 2006	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	Met primary
Phase 3	NCT00252863	Dec 2004 → May 2006	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00144846	Sep 2004 → Feb 2006	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00085774	Jun → Sep 2004	exercise-induced bronchoconstriction	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT02177253	Oct 2002 → Mar 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00382889	Aug 2002 → Sep 2004	asthma	Chiesi Farmaceutici S.p.A.	Completed	Met primary
Phase 3	NCT00665600	Feb 2002 → Mar 2003	chronic obstructive pulmonary disease	Sumitomo Pharma America, Inc.	Completed	No outcome recorded
Phase 3	NCT02182700	Jul 1998 → Dec 1999	asthma	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 3	NCT00000577	Sep 1993 → Jul 2008	asthma, lung disorder	Milton S. Hershey Medical Center	Withdrawn	No outcome recorded

Phase 445 trials · 2 met primary · 2 missed
Phase 4	NCT07426458	Apr 2026 → Apr 2028 expected	asthma	University of Miami	Recruiting	No outcome recorded
Phase 4	NCT07166939	Nov 2025 → Jun 2027 expected	acute asthma	Massachusetts General Hospital	Recruiting	No outcome recorded
Phase 4	NCT06825013	Nov 2024 → Jan 2027 expected	chronic obstructive pulmonary disease	Dr. J. Alberto Neder	Recruiting	No outcome recorded
Phase 4	NCT06563102	Sep 2024 → Feb 2026	asthma	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT06158893	Aug 2024 → Aug 2025	—	Assiut University	Unknown	No outcome recorded
Phase 4	NCT06422689	May 2024 → Feb 2027 expected	asthma	AstraZeneca	Active not recruiting	No outcome recorded
Phase 4	NCT04184609	Jul → Nov 2023	childhood onset asthma, obesity disorder	Ohio State University	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT05084222	Nov 2021 → Jun 2023	asthma	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 4	NCT05087693	Nov 2021 → Aug 2023	bronchial disorder	University of British Columbia	Completed	No outcome recorded
Phase 4	NCT04677959	Feb 2021 → Mar 2022	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 4	NCT04606394	Dec 2020 → Dec 2021	chronic obstructive pulmonary disease	Pulmonary Research Institute of Southeast Michigan	Completed	Missed primary
Phase 4	NCT03890666	Oct 2020 → Oct 2021	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 4	NCT04012138	Dec 2019 → Dec 2025	—	Nantes University Hospital	Completed	No outcome recorded
Phase 4	NCT04207840	Dec 2019	anaphylaxis, asthma	Amphastar Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 4	NCT03924635	Aug 2019 → Dec 2022	asthma	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT03586544	Sep 2018 → Mar 2020	childhood onset asthma, exercise-induced bronchoconstriction, obesity disorder	University of Nevada, Las Vegas	Terminated	No outcome recorded
Phase 4	NCT02966184	Sep → Oct 2018	status asthmaticus	Norton Healthcare	Terminated	No outcome recorded
Phase 4	NCT03493503	Apr 2017 → May 2019	status asthmaticus	Erasmus Medical Center	Completed	No outcome recorded
Phase 4	NCT02914652	Oct 2016 → Jul 2017	ventricular septal defect	University of Aarhus	Completed	Missed primary
Phase 4	NCT03044938	Aug 2016	asthma	Ibirapuera University	Completed	No outcome recorded
Phase 4	NCT02797275	Jun 2016 → Dec 2026 expected	obstructive lung disease	University of California, San Francisco	Active not recruiting	No outcome recorded
Phase 4	NCT03199976	Apr 2016 → Nov 2020	asthma, bronchitis, obstructive lung disease	Helsinki University Central Hospital	Terminated	Met primary
Phase 4	NCT02447250	Oct 2013 → Dec 2014	bronchopulmonary dysplasia	Oregon Health and Science University	Completed	No outcome recorded
Phase 4	NCT02405598	Oct 2013 → Jul 2015	glycogen storage disease due to acid maltase deficiency, infantile onset	National Taiwan University Hospital	Completed	No outcome recorded
Phase 4	NCT01903785	May 2013 → Dec 2014	exercise-induced bronchoconstriction	University of British Columbia	Completed	No outcome recorded
Phase 4	NCT01721291	Oct 2012 → Nov 2017	asthma, chronic obstructive pulmonary disease	Imperial College London	Completed	No outcome recorded
Phase 4	NCT02103374	Jan 2012 → Dec 2015	chronic obstructive pulmonary disease	University Hospital, Tours	Completed	No outcome recorded
Phase 4	NCT01112241	Apr → May 2010	transplant-related bronchiolitis obliterans	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy	Completed	No outcome recorded
Phase 4	NCT02877537	Oct 2008 → Apr 2012	asthma	Central Hospital, Nancy, France	Completed	No outcome recorded
Phase 4	NCT00783250	Sep 2008 → Aug 2011	chronic obstructive pulmonary disease	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Terminated	No outcome recorded
Phase 4	NCT00440245	Feb 2007 → Jul 2010	asthma, chronic obstructive pulmonary disease	University of Saskatchewan	Completed	No outcome recorded
Phase 4	NCT00388882	Oct 2006 → Oct 2007	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00385359	Oct 2006 → ?	asthma	University Health Network, Toronto	Unknown	No outcome recorded
Phase 4	NCT00359788	Jul 2006 → Apr 2008	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 4	NCT00354354	Mar 2006 → Jul 2009	chronic obstructive pulmonary disease	Queen's University	Completed	No outcome recorded
Phase 4	NCT00273689	Dec 2005 → Sep 2007	exercise-induced bronchoconstriction	University of New Mexico	Completed	No outcome recorded
Phase 4	NCT00325767	May 2004 → Sep 2005	mucus inspissation of respiratory tract	Johns Hopkins University	Completed	No outcome recorded
Phase 4	NCT00272753	Apr 2004 → Nov 2005	asthma	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT07436104	Jan 2004 → Dec 2015	asthma, chronic diarrheal disease, chronic obstructive pulmonary disease, hypertensive disorder +2	MAHAN Trust	Completed	No outcome recorded
Phase 4	NCT00273962	May 2002 → Nov 2003	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00361452	Dec 2000 → May 2001	respiratory syncytial virus bronchiolitis	Rambam Health Care Campus	Terminated	No outcome recorded
Phase 4	NCT02235428	Sep 1998	asthma	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 4	NCT02182713	May → Sep 1998	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02182856	Feb 1998 → Jul 2000	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00940927	Jul 1993 → Oct 1994	asthma	Nemours Children's Clinic	Completed	No outcome recorded

Phase not applicable44 trials · 2 met primary · 1 missed
—	NCT07378605	Jan → Mar 2026 overdue	—	Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital	Not yet recruiting	No outcome recorded
—	NCT06426082	Nov 2024 → Aug 2025 overdue	cardiovascular-kidney-metabolic syndrome	Universidad de Almeria	Not yet recruiting	No outcome recorded
—	NCT06276231	Jul 2024 → Mar 2026	urinary tract obstruction	Oman Medical Speciality Board	Unknown	No outcome recorded
—	NCT06754631	Apr → Sep 2024	childhood onset asthma	Muhammad Aamir Latif	Completed	No outcome recorded
—	NCT05932316	May 2023 → Apr 2024	bronchiectasis, bronchiolitis, cystic fibrosis, immunodeficiency disease +1	Rambam Health Care Campus	Unknown	No outcome recorded
—	NCT05914285	Apr 2023 → Jun 2025 overdue	chronic obstructive pulmonary disease	Yonsei University	Active not recruiting	No outcome recorded
—	NCT05786950	Jan → Jul 2023	chronic obstructive pulmonary disease	The First Affiliated Hospital of Guangzhou Medical University	Completed	No outcome recorded
—	NCT05589441	Oct 2022 → Oct 2023	—	First Affiliated Hospital Xi'an Jiaotong University	Unknown	Met primary
—	NCT04912596	Aug 2022 → Jan 2025 overdue	asthma	Intech Biopharm Ltd.	Recruiting	No outcome recorded
—	NCT04402658	Aug 2022 → May 2023	substance abuse	Norwegian School of Sport Sciences	Withdrawn	No outcome recorded
—	NCT05241288	Mar 2022 → Feb 2023	chronic obstructive pulmonary disease	University of North Carolina, Chapel Hill	Completed	No outcome recorded
—	NCT04914273	Jun → Aug 2021	—	Fraunhofer-Institute of Toxicology and Experimental Medicine	Completed	No outcome recorded
—	NCT04615611	Nov 2020 → Nov 2021	—	University of Copenhagen	Unknown	No outcome recorded
—	NCT04558190	Sep 2020 → Nov 2021	—	University of Copenhagen	Completed	No outcome recorded
—	NCT03524066	Apr → Dec 2018	—	Fraunhofer-Institute of Toxicology and Experimental Medicine	Completed	No outcome recorded
—	NCT03091504	Sep 2017 → Mar 2018	—	Rush University Medical Center	Completed	No outcome recorded
—	NCT03071731	Apr 2017 → Jun 2019	chronic obstructive pulmonary disease	Laval University	Unknown	No outcome recorded
—	NCT03271905	Apr 2017 → Dec 2018	asthma, chronic obstructive pulmonary disease	Federal University of Rio Grande do Norte	Unknown	No outcome recorded
—	NCT02925130	Oct 2016 → Sep 2017	—	University Hospital, Grenoble	Completed	No outcome recorded
—	NCT02818270	Jun → Dec 2016	chronic obstructive pulmonary disease	Chang Gung University	Completed	No outcome recorded
—	NCT02740660	Apr 2016 → Oct 2017	—	Pennington Biomedical Research Center	Completed	No outcome recorded
—	NCT02678949	Mar → Aug 2016	childhood onset asthma	Hospital Infantil de Mexico Federico Gomez	Unknown	No outcome recorded
—	NCT02802111	Jun 2015 → Sep 2017	—	Children's Hospital Los Angeles	Completed	No outcome recorded
—	NCT02296047	Dec 2014 → May 2015	chronic obstructive pulmonary disease	Zhujiang Hospital	Completed	No outcome recorded
—	NCT03062904	Feb 2014 → Dec 2019	—	Assistance Publique - Hôpitaux de Paris	Unknown	No outcome recorded
—	NCT02551276	Nov 2013 → Nov 2014	upper limb hypertrophy	University of Copenhagen	Completed	No outcome recorded
—	NCT02218398	May 2013 → Jun 2015	chronic obstructive pulmonary disease	Beijing Chao Yang Hospital	Unknown	No outcome recorded
—	NCT01655199	Sep 2012 → Jul 2014	chronic obstructive pulmonary disease	Laval University	Unknown	No outcome recorded
—	NCT01799109	Nov 2011 → Jan 2012	asthma	Chongqing Medical University	Completed	No outcome recorded
—	NCT01323010	Sep 2011 → Dec 2013	asthma	University of Sao Paulo	Completed	Missed primary
—	NCT01521572	Jun 2011 → Jan 2012	obstructive lung disease	Rio de Janeiro State University	Unknown	No outcome recorded
—	NCT01255449	Dec 2010 → Mar 2012	disease related to hematopoietic stem cell transplant, transplant-related bronchiolitis obliterans	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy	Completed	No outcome recorded
—	NCT01196377	Sep → Oct 2010	acute asthma	Vanderbilt University Medical Center	Completed	No outcome recorded
—	NCT01067534	Feb 2010 → Jan 2011	isoproterenol-mediated vasodilatation	University of Patras	Completed	No outcome recorded
—	NCT01880723	May 2009 → Jul 2012	cystic fibrosis	University of Arizona	Completed	No outcome recorded
—	NCT00498251	Sep 2004 → Jun 2007	acute lung injury	University Hospital, Geneva	Completed	No outcome recorded
—	NCT00114478	Nov 2003 → May 2006	bronchiolitis	Kern Medical Center	Unknown	Met primary
—	NCT00162422	Aug 2003 → ?	asthma	Hadassah Medical Organization	Unknown	No outcome recorded
—	NCT00162487	Aug 2002 → ?	chronic renal failure syndrome	Hadassah Medical Organization	Unknown	No outcome recorded
—	NCT00039988	Nov 2001 → Mar 2006	multiple sclerosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00027391	Sep 2001 → Aug 2004	muscular dystrophy, scapulohumeral	FDA Office of Orphan Products Development	Completed	No outcome recorded
—	NCT00162396	Aug 1999 → ?	asthma	Hadassah Medical Organization	Unknown	No outcome recorded
—	NCT00004685	Jan 1998 → Sep 2000	facioscapulohumeral muscular dystrophy	Ohio State University	Completed	No outcome recorded
—	NCT00005110	—	cystic fibrosis	National Center for Research Resources (NCRR)	Suspended	No outcome recorded

Comparator or background therapy221 trials
Phase 0	NCT04901715 Comparator	Jun 2021 → Jul 2024	primary ciliary dyskinesia	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 1	NCT05366764 Background	Jun 2022 → Feb 2023	asthma	Sanofi	Completed	No outcome recorded
Phase 1	NCT05035862 Background	Mar → Dec 2022	asthma	Emory University	Terminated	No outcome recorded Stop: Business
Phase 1	NCT04929626 Comparator	Jan → Nov 2022	status asthmaticus	Ziauddin University	Completed	No outcome recorded
Phase 1	NCT04848662 Background	May → Jul 2021	asthma	Bond Avillion 2 Development LP	Completed	No outcome recorded
Show all 221 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 27

Date	Issuer	Release
2025-10-22	GlaxoSmithKline	Results GSK announces positive pivotal phase III data for next-generation low carbon version of Ventolin (salbutamol) metered dose inhaler gsk.com ↗ Data confirm that the formulation of salbutamol MDI containing an innovative low carbon propellant HFA-152a shows therapeutic equivalence and is comparable in safety to salbutamol MDI containing the current propellant, HFA-134a.
2025-05-19	AstraZeneca	Results Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for Airsupra as standard of care for as-needed rescue treatment in asthma astrazeneca.com ↗ The BATURA trial demonstrated treatment with Airsupra significantly reduced the risk of a severe exacerbation by 47% (5.1%, 9.1%, hazard ratio [HR] 0.53; 95% confidence interval [CI], 0.39, 0.73; p<0.001) when compared with albuterol alone.
2024-10-07	AstraZeneca	Results Airsupra demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial astrazeneca.com ↗ Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysis
2024-10-06	DevPro Biopharma	Results DevPro Biopharma and Bespak Complete Early Feasibility Studies devprobiopharma.com ↗ DevPro Biopharma and Bespak Complete Early Feasibility Studies
2024-05-22	Amphastar Pharmaceuticals, Inc.	Regulatory Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol amphastar.com ↗ Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that the U.S. Food and Drug Administration ("FDA") has granted approval for the Company's Abbreviated New Drug Application ("ANDA") for Albuterol Sulfate Inhalation Aerosol, previously known as AMP-008.
2023-01-11	AstraZeneca	Regulatory Airsupra (PT027) approved in the US for asthma astrazeneca.com ↗ Airsupra (albuterol/budesonide), formerly known as PT027, has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.
2022-11-09	AstraZeneca	Regulatory PT027 recommended by FDA Advisory Committee as new rescue treatment for asthma astrazeneca.com ↗
2022-09-07	Teva Branded Pharmaceutical Products R&D, Inc.	Results CONNECT1 Study Published in Journal of Allergy and Clinical Immunology: In Practice Evaluates the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder and Digihaler System to Help Improve Asthma Management tevapharm.com ↗ The study found patients who used the ProAir Digihaler had reductions in weekly average daily short-acting beta agonist (SABA) inhalations and an increase in weekly number of SABA-free days.
2022-05-17	Teva Branded Pharmaceutical Products R&D, Inc.	Results Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges tevapharm.com ↗ Among the study findings, nearly one-third of asthma patients made 138 or more inhalations during the 12-week study period, which was equivalent to 600 or more inhalations, or three or more canisters, per year.
2022-05-15	AstraZeneca	Results PT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation compared to albuterol by 27% in patients with asthma astrazeneca.com ↗ Compared with albuterol rescue, PT027 at the 180mcg albuterol/160mcg budesonide dose reduced the risk of a severe exacerbation by 27% (p<0.001) in adults and adolescents.
2021-09-09	AstraZeneca	Results Fixed-dose combination of albuterol and budesonide (PT027) demonstrated significant benefits for asthma patients in MANDALA and DENALI Phase III trials astrazeneca.com ↗ The MANDALA trial met the primary endpoint, with PT027 demonstrating statistically significant and clinically meaningful reductions in the risk of severe exacerbations compared to albuterol, when used as a rescue medicine in response to symptoms.
2021-05-10	Teva Branded Pharmaceutical Products R&D, Inc.	Results Teva to Highlight Research in Respiratory Care at Upcoming 2021 American Thoracic Society International Conference tevapharm.com ↗ Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),today announced that it will present two new e-posters at the upcoming American Thoracic Society (ATS) International Conference, taking place virtually May 14-19, 2021.
2021-03-15	CuraSen Therapeutics, Inc.	Results CuraSen Therapeutics Announces Phase 1 Clinical Data Demonstrating that Salbutamol, a Beta-2 Adrenoceptor Agonist, Significantly Increases Cerebral Perfusion, a Key Marker in Neurodegenerative Disease curasen.com ↗ CuraSen Therapeutics, Inc., a privately held, clinical-stage biotechnology company, announced Phase 1 proof-of-principle data demonstrating that salbutamol, a drug approved to treat respiratory disease, significantly improved brain perfusion as measured by increased cerebral blood flow (CBF) in healthy subjects.
2020-08-25	Lupin Limited	Regulatory Lupin Receives Approval for Generic Albuterol Sulphate MDI lupin.com ↗ Lupin Limited (Lupin) announced today that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Albuterol Sulfate Inhalation Aerosol, 90 mcg (base)/actuation, a generic version of ProAir® HFA.
2020-05-19	Teva Canada	Regulatory Teva Canada Secures Salbutamol Inhalers from its Global Supply Chain to Mitigate Shortage in Canadian Market tevacanada.com ↗ Working closely with Health Canada and through the Interim Order, Teva Canada was able to expedite approval to import a supply of Pr Salamol CFC-Free Inhaler to Canada.
2019-05-20	AstraZeneca	Results New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever astrazeneca.com ↗ Symbicort Turbuhaler demonstrated a 51% reduction in the rate of annual asthma exacerbations compared to albuterol.
2018-12-21	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ (albuterol sulfate 117 mcg) Inhalation Powder tevapharm.com ↗
2016-04-29	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces FDA Approval of ProAir RespiClick® (albuterol sulfate) Inhalation Powder for Pediatric Asthma Patients Ages 4 to 11 tevapharm.com ↗
2015-09-10	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces FDA Acceptance of a Supplemental New Drug Application for ProAir® RespiClick (albuterol sulfate) Inhalation Powder for Pediatric Patients tevapharm.com ↗ “The acceptance of the pediatric filing for ProAir® RespiClick by the FDA represents an important step forward for Teva in our mission to better serve patients living with respiratory conditions, such as asthma and EIB,”
2015-04-01	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces FDA Approval of ProAir® RespiClick tevapharm.com ↗
2014-07-31	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Reports Second Quarter 2014 Results tevapharm.com ↗ the FDA acceptance of our albuterol MDPI NDA
2014-07-14	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces FDA Acceptance of NDA Filing for Investigational Short-Acting Beta-Agonist (SABA) Inhaler (Albuterol MDPI) tevapharm.com ↗ The NDA for albuterol MDPI has been accepted by the FDA for standard review, with a FDA Regulatory Action expected in March 2015.
2013-11-08	Teva Branded Pharmaceutical Products R&D, Inc.	Results Survey Data Reinforces Patient Benefit of Asthma Rescue Inhalers with Integrated Dose Counters tevapharm.com ↗ The incidence rate of respiratory-related ER visits in the total study population was estimated to be 45 percent lower in the dose counter cohort compared with the non-dose counter cohort.
2011-10-07	Boehringer Ingelheim	Regulatory FDA Approves Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray for the Treatment of Patients with Chronic Obstructive Pulmonary Disease prnewswire.com ↗
2010-04-13	Boehringer Ingelheim	Regulatory FDA Maintains Essential Use Status of Combivent(R) (ipratropium bromide and albuterol sulfate) Inhalation Aerosol Through 2013 prnewswire.com ↗
2008-09-24	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva's Proair® HFA, the Market Leading Albuterol Inhaler, Receives New Pediatric Indication tevapharm.com ↗ Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved ProAir® HFA (albuterol sulfate) Inhalation Aerosol for use in patients as young as 4 years of age.
2008-01-02	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Approval Of Generic Duoneb® tevapharm.com ↗ Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA)announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application(ANDA) to market its generic version of Dey's bronchodilator, DuoNeb® (Albuterol Sulfate and Ipratropium Bromide) Inhalation Solution, 3 mg (0.083%)and 0.5 mg (0.017%).

All press releases naming this drug 37 releases

Date	Issuer	Release
2025-10-22	GlaxoSmithKline	GSK announces positive pivotal phase III data for next-generation low carbon version of Ventolin (salbutamol) metered dose inhaler gsk.com ↗
2025-05-19	AstraZeneca	Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for Airsupra as standard of care for as-needed rescue treatment in asthma astrazeneca.com ↗
2024-10-07	AstraZeneca	Airsupra demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial astrazeneca.com ↗
2024-10-06	DevPro Biopharma	DevPro Biopharma and Bespak Complete Early Feasibility Studies devprobiopharma.com ↗
2024-05-22	Amphastar Pharmaceuticals, Inc.	Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol amphastar.com ↗
2023-11-21	GlaxoSmithKline	GSK announces major step towards sustainability ambitions with advancement of low carbon Ventolin programme to Phase III trials gsk.com ↗
2023-01-11	AstraZeneca	Airsupra (PT027) approved in the US for asthma astrazeneca.com ↗
2022-11-09	AstraZeneca	PT027 recommended by FDA Advisory Committee as new rescue treatment for asthma astrazeneca.com ↗
2022-09-07	Teva Branded Pharmaceutical Products R&D, Inc.	CONNECT1 Study Published in Journal of Allergy and Clinical Immunology: In Practice Evaluates the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder and Digihaler System to Help Improve Asthma Management tevapharm.com ↗
2022-08-29	Teva Branded Pharmaceutical Products R&D, Inc.	Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022 tevapharm.com ↗
2022-05-17	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges tevapharm.com ↗
2022-05-15	AstraZeneca	PT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation compared to albuterol by 27% in patients with asthma astrazeneca.com ↗
2022-05-12	Teva Branded Pharmaceutical Products R&D, Inc.	Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting tevapharm.com ↗
2021-09-09	AstraZeneca	Fixed-dose combination of albuterol and budesonide (PT027) demonstrated significant benefits for asthma patients in MANDALA and DENALI Phase III trials astrazeneca.com ↗
2021-05-10	Teva Branded Pharmaceutical Products R&D, Inc.	Teva to Highlight Research in Respiratory Care at Upcoming 2021 American Thoracic Society International Conference tevapharm.com ↗
2021-03-15	CuraSen Therapeutics, Inc.	CuraSen Therapeutics Announces Phase 1 Clinical Data Demonstrating that Salbutamol, a Beta-2 Adrenoceptor Agonist, Significantly Increases Cerebral Perfusion, a Key Marker in Neurodegenerative Disease curasen.com ↗
2020-08-25	Lupin Limited	Lupin Receives Approval for Generic Albuterol Sulphate MDI lupin.com ↗
2020-07-13	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Availability of ProAir® Digihaler® (albuterol sulfate 117 mcg) Inhalation Powder for Patients with Asthma and COPD tevapharm.com ↗
2020-05-19	Teva Canada	Teva Canada Secures Salbutamol Inhalers from its Global Supply Chain to Mitigate Shortage in Canadian Market tevacanada.com ↗
2020-05-14	Teva Canada	Important Safety Information - Importation of Teva UK-labelled Salamol CFC-Free (Salbutamol Sulfate) Inhaler due to Shortage tevacanada.com ↗
2020-05-14	Teva Canada	Availability of UK-Labelled Product – Salbutamol Metered Dose Inhaler (MDI) tevacanada.com ↗
2019-05-20	AstraZeneca	New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever astrazeneca.com ↗
2018-12-21	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ (albuterol sulfate 117 mcg) Inhalation Powder tevapharm.com ↗
2016-04-29	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FDA Approval of ProAir RespiClick® (albuterol sulfate) Inhalation Powder for Pediatric Asthma Patients Ages 4 to 11 tevapharm.com ↗
2015-09-10	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FDA Acceptance of a Supplemental New Drug Application for ProAir® RespiClick (albuterol sulfate) Inhalation Powder for Pediatric Patients tevapharm.com ↗
2015-04-01	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FDA Approval of ProAir® RespiClick tevapharm.com ↗
2014-11-07	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Presents Data for Investigational Short-Acting Beta-Agonist Inhaler (Albuterol MDPI) at 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology tevapharm.com ↗
2014-07-31	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Reports Second Quarter 2014 Results tevapharm.com ↗
2014-07-14	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FDA Acceptance of NDA Filing for Investigational Short-Acting Beta-Agonist (SABA) Inhaler (Albuterol MDPI) tevapharm.com ↗
2013-11-08	Teva Branded Pharmaceutical Products R&D, Inc.	Survey Data Reinforces Patient Benefit of Asthma Rescue Inhalers with Integrated Dose Counters tevapharm.com ↗
2013-05-17	Boehringer Ingelheim	Transition to Propellant-Free Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray Nears Completion prnewswire.com ↗
2012-09-18	Boehringer Ingelheim	Boehringer Ingelheim Launches Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray for Chronic Obstructive Pulmonary Disease prnewswire.com ↗
2011-10-10	Boehringer Ingelheim	FDA Approves Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray for the Treatment of Patients with Chronic Obstructive Pulmonary Disease prnewswire.com ↗
2011-10-07	Boehringer Ingelheim	FDA Approves Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray for the Treatment of Patients with Chronic Obstructive Pulmonary Disease prnewswire.com ↗
2010-04-13	Boehringer Ingelheim	FDA Maintains Essential Use Status of Combivent(R) (ipratropium bromide and albuterol sulfate) Inhalation Aerosol Through 2013 prnewswire.com ↗
2008-09-24	Teva Branded Pharmaceutical Products R&D, Inc.	Teva's Proair® HFA, the Market Leading Albuterol Inhaler, Receives New Pediatric Indication tevapharm.com ↗
2008-01-02	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Approval Of Generic Duoneb® tevapharm.com ↗

Evidence & citations 56 cited values

Every value below carries the sentence it was read from. 430 sources stand behind the page.

Field	Value	Cited text
Known as	salbutamol	“A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of...” NCT02139644 ↗ 229 “A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of...” NCT01576718 ↗ “A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of...” NCT01479621 ↗ “Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or...” NCT02513160 ↗ “A Study Designed to Determine if the Drugs Albuterol (Salbutamol) and Fluticasone Have an Effect on the Pharmacokinetics of the Investigational Product Technosphere® Insulin...” NCT00674050 ↗ “Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma...” NCT02040766 ↗ “Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma...” NCT02040779 ↗ “In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods.” NCT04643158 ↗ “Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd.), 100 μg/press, 200 press, 100 μg each time (when needed), no more than 8 press daily for 12 weeks.” NCT03169504 ↗ “Three concentrations of topical salbutamol gel will be compared, in a group-wise fashion, with a placebo administration at one incision site on each arm of the trial subjects.” NCT03514615 ↗ “Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1” NCT02345161 ↗ Show 219 more sources
Known as	(Proventil )	“The effects of albuterol delivered via AS MDI and Proventil on bronchodilation were equivalent, supporting the selection of AS MDI 180 µg to be taken into Phase III clinical...” PMID 34089147 ↗ Jun 2021 2 “(Proventil ®)” NCT01987219 ↗ NCT02271334 ↗
Known as	A004	“This 12-week clinical study evaluates the safety and efficacy of Albuterol Sulfate HFA Inhalation Aerosol (Albuterol-HFA, or: A004), Armstrong's proposed HFA formulation of...” NCT00635505 ↗
Known as	A006	“A006 (Albuterol Dry Powder Inhaler (DPI)), in comparison with those of an active control, Proventil-HFA (Albuterol Metered Dose Inhaler (MDI))” NCT01189396 ↗ 3 “A006 albuterol inhalation powder, 120 mcg/inhalation, one inhalation” NCT01174732 ↗ “A006, an Albuterol dry powder inhaler (DPI)” NCT01581177 ↗ NCT02271334 ↗
Known as	ABS	“This is a Phase 3B, 12-week, multicenter, open-label study to evaluate the relationship between albuterol sulfate (ABS) eMDPI and clinical asthma exacerbation (CAE) in adult...” NCT02969408 ↗ 2 “Albuterol sulfate (ABS) dry powder inhaler with an integrated electronic module (eMDPI)” NCT06664619 ↗ “fluticasone propionate (Fp) and albuterol sulfate (ABS), delivered in combination” NCT06290102 ↗
Known as	aerolin nebulis	“Nebulized bronchodilator drugs will be Salbutamol Sulfate (aerolin nebulis) and ipratropium bromide (atrovent) diluted in a saline solution (saline 0.9%) in 3 ml.” NCT03271905 ↗
Known as	ALB	“comparing the fixed combination of ipratropium and albuterol (IB+ALB) to albuterol alone (ALB).” PMID 18403223 ↗ Mar 2008
Known as	ALB-HFA	“albuterol hydrofluoroalkaline (ALB-HFA) alone after 4 weeks” PMID 27130202 ↗ Apr 2016
Known as	albuterol	“BACKGROUND: Treatment guidelines recommend the regular use of inhaled corticosteroids for patients with mild persistent asthma. We investigated whether the symptom-driven use...” PMID 17507703 ↗ May 2007 212 “Participants were randomly assigned in a 1:1 ratio to a fixed-dose combination of 180 μg of albuterol and 160 μg of budesonide (with each dose consisting of two inhaler...” PMID 40388330 ↗ May 2025 “participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid...” NCT06272370 ↗ “This study evaluates the efficacy, dose-ranging and safety profiles of A006, an Albuterol dry powder inhaler (DPI), in the dose range of 110 to 220 mcg per dose in comparison...” NCT02210806 ↗ “The aim is to asses that using Nebulized Hypertonic Saline with bronchodilators (albuterol) may reduce the days of hospitalization and improve clinical outcomes in patients...” NCT01238848 ↗ “The effects of albuterol delivered via AS MDI and Proventil on bronchodilation were equivalent, supporting the selection of AS MDI 180 µg to be taken into Phase III clinical...” PMID 34089147 ↗ Jun 2021 “The purpose of the project is to investigate whether the use of a WADA approved dose of salbutamol (albuterol/Ventoline) has a performance-enhancing effect on sprint...” NCT04402658 ↗ “All subjects received fluticasone furoate/vilanterol ELLIPTA dry-powder inhalers for maintenance and salbutamol/albuterol metered-dose inhalers for rescue, with a sensor...” PMID 33334936 ↗ Jun 2021 “In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods.” NCT04643158 ↗ “FDA approval of Airsupra (with both albuterol and budesonide in one inhaler) provides a unique opportunity to introduce ICS (along with albuterol) to ED patients with acute asthma.” NCT07166939 ↗ “Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period” NCT01641692 ↗ Show 202 more sources
Known as	Albuterol eMDPI	“Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) DS with 4 component devices:” NCT03890666 ↗
Known as	Albuterol eMDPI DS	“Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) DS with 4 component devices:” NCT03890666 ↗
Known as	Albuterol HCl	“Albuterol HCl Inhalation Solution” NCT00685126 ↗
Known as	albuterol MDPI	“OBJECTIVE: To evaluate albuterol MDPI efficacy and safety in patients with exercise-induced bronchoconstriction (EIB).” PMID 26475054 ↗ Sep 2015
Known as	Albuterol Spiromax	“Albuterol Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) containing a blend of albuterol sulfate with alpha-lactose monohydrate.” NCT01791972 ↗ 3 “Albuterol Spiromax® 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose” NCT01844401 ↗ “Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)” NCT01857323 ↗ “Albuterol Spiromax® delivers 90 mcg albuterol per inhalation.” NCT01058863 ↗
Known as	albuterol sulfate	“Study to demonstrate the comparability of two puffs of Combivent hydrofluoroalkane (HFA) inhalation aerosol (18 mcg ipratropium bromide/100 mcg albuterol sulfate / per puff) to...” NCT02182674 ↗ 43 “The objective of this study was to investigate the bioequivalence of Mylan's albuterol sulfate extended-release 8 mg tablets to Pliva's VoSpire™ ER 8 mg tablets following a...” NCT00649779 ↗ “This is a Phase 3B, 12-week, multicenter, open-label study to evaluate the relationship between albuterol sulfate (ABS) eMDPI and clinical asthma exacerbation (CAE) in adult...” NCT02969408 ↗ “Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administered via inhalation at a dose of 2 inhalations every 4 to 6 hours as rescue medication among participants...” NCT00550550 ↗ “Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administed via inhalation at a dose of 2 inhalations every 4 to 6 hours, as needed, as rescue medication for asthma.” NCT00562159 ↗ “Measurements were made at baseline and at 30, 60 and 90 min following the administration of a nebulized β(2)-agonist (albuterol sulfate, 2.5 mg diluted in 3 ml normal saline).” PMID 21889619 ↗ Aug 2011 “Co-suspension Delivery™ Technology has been developed for the administration of albuterol sulfate pressurised inhalation suspension via metered-dose inhaler (AS MDI, PT007).” PMID 34089147 ↗ Jun 2021 “Co-suspension Delivery™ Technology has been developed for the administration of albuterol sulfate pressurised inhalation suspension via metered-dose inhaler (AS MDI, PT007).” PMID 34089147 ↗ Jun 2021 “The drug product albuterol sulfate DPI, TBS-7, is a single dose inhalation product of albuterol sulfate containing 240 ug albuterol sulphate (200 ug of albuterol)” NCT01252758 ↗ “Participants will receive Albuterol Sulfate MDI 90 μg per Actuation 1 to 6 doses (2 inhalations/dose) per day as needed via Oral inhalation route.” NCT05505734 ↗ “Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/90 μg per puff. Two puffs to administer 160/180 μg dose.” NCT04848662 ↗ Show 33 more sources
Known as	Albuterol Sulfate Acu-30 DPI	“A Stepwise, Rising Dose Study of Male Subjects With Mild Intermittent Asthma to Assess the Topical Safety and Tolerability of Albuterol Sulfate Acu-30™ DPI Compared With...” NCT00565591 ↗
Known as	Albuterol Sulfate HFA	“Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation” NCT04912596 ↗
Known as	Albuterol-HFA	“This 12-week clinical study evaluates the safety and efficacy of Albuterol Sulfate HFA Inhalation Aerosol (Albuterol-HFA, or: A004), Armstrong's proposed HFA formulation of...” NCT00635505 ↗
Known as	Albuterol-sulphate	“The drug product albuterol sulfate DPI, TBS-7, is a single dose inhalation product of albuterol sulfate containing 240 ug albuterol sulphate (200 ug of albuterol)” NCT01252758 ↗ 1 “Albuterol-sulphate (Proventil ®) Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours” NCT01987219 ↗
Known as	Albuterol/Salbutamol	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02478398 ↗ 1 NCT00070707 ↗
Known as	Armstrong Albuterol HFA	“albuterol (Armstrong Albuterol HFA)” NCT00634829 ↗
Known as	AS MDI	“Co-suspension Delivery™ Technology has been developed for the administration of albuterol sulfate pressurised inhalation suspension via metered-dose inhaler (AS MDI, PT007).” PMID 34089147 ↗ Jun 2021 2 “Albuterol Sulfate metered dose inhaler [AS MDI] - PT007)” NCT06644924 ↗ “Albuterol sulfate AS MDI (PT007)” NCT03847896 ↗
Known as	etinoline	“At the acute stage of asthma : etinoline,twice a day for 7 days” NCT02341573 ↗
Known as	Pro-Air	“Albuterol (Pro-Air) hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment...” NCT01772368 ↗
Known as	PROAIR HFA	“Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation” NCT04912596 ↗ 5 “ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose” NCT01844401 ↗ “PROAIR® HFA (Albuterol Sulfate) Inhalation Aerosol, eq 90 mcg Base” NCT03549897 ↗ “PROAIR™ HFA (Albuterol Sulfate) Breath Actuated Inhalation Aerosol” NCT00308685 ↗ “ProAir® HFA delivers 90 mcg of albuterol per inhalation.” NCT01058863 ↗ “PROAIR® HFA (albuterol sulfate) Inhalation Aerosol” NCT03528577 ↗
Known as	ProAir RespiClick	“ProAir® RespiClick, Albuterol multi-dose dry powder inhaler (MDPI)” NCT01857323 ↗
Known as	ProAir RespiClick, Albuterol multi-dose dry powder inhaler (MDPI)	“ProAir® RespiClick, Albuterol multi-dose dry powder inhaler (MDPI)” NCT01218009 ↗ 1 “ProAir® RespiClick, Albuterol multi-dose dry powder inhaler (MDPI)” NCT01058863 ↗
Known as	Proventil HFA	“A recent study demonstrated that patients with mild asthma and the Arg/Arg variant at the 16th amino acid position have improved lung function and asthma control when albuterol...” NCT00521222 ↗ 2 “A006 (Albuterol Dry Powder Inhaler (DPI)), in comparison with those of an active control, Proventil-HFA (Albuterol Metered Dose Inhaler (MDI))” NCT01189396 ↗ “Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study.” NCT00577655 ↗
Known as	PT007	“Co-suspension Delivery™ Technology has been developed for the administration of albuterol sulfate pressurised inhalation suspension via metered-dose inhaler (AS MDI, PT007).” PMID 34089147 ↗ Jun 2021 2 “Albuterol Sulfate metered dose inhaler [AS MDI] - PT007)” NCT06644924 ↗ “Albuterol sulfate AS MDI (PT007)” NCT03847896 ↗
Known as	Racemic albuterol	“Racemic albuterol (0.63, 1.25 mg or 2.5 mg); the first three doses will be delivered every 20 minutes for the first hour.” NCT00685126 ↗
Known as	S-albuterol	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00320034 ↗
Known as	SALB	“Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL).” NCT02782052 ↗
Known as	SalbG	“(Salbutamol Generic, SalbG)” NCT05884970 ↗
Known as	SalbR	“reference product (Ventolin, Salbutamol Reference, SalbR)” NCT05884970 ↗
Known as	Salbultamol	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00990847 ↗
Known as	Salbutamol Generic	“(Salbutamol Generic, SalbG)” NCT05884970 ↗
Known as	Salbutamol Reference	“reference product (Ventolin, Salbutamol Reference, SalbR)” NCT05884970 ↗
Known as	Salbutamol Sandoz	“"100 mcg Salbutamol Sandoz" and "300 mcg Salbutamol Sandoz"” NCT05884970 ↗
Known as	Salbutamol sulfate	“Each participant received aerosolized salbutamol sulfate consisting of 1 mL Farcolin® solution containing 6050 µg salbutamol sulfate diluted with 2 mL normal saline placed...” NCT07633223 ↗ 8 “Nebulized bronchodilator drugs will be Salbutamol Sulfate (aerolin nebulis) and ipratropium bromide (atrovent) diluted in a saline solution (saline 0.9%) in 3 ml.” NCT03271905 ↗ “Nebulization of ipratropium bromide/salbutamol sulfate (500 µg/2.5 mg) before the administration of the Glittre ADL-test” NCT03071731 ↗ “Salbutamol will be delivered using a Babyhaler spacer device. Ventolin will be used, brandname for Salbutamol sulfate.” NCT04584034 ↗ “Fluticasone Propionate/Salbutamol Sulfate. Oral inhalation powder.” NCT06052267 ↗ “Salbutamol sulfate 120 mcg + Ipratropium bromide 20 mcg per puff” NCT02182713 ↗ “Salbutamol (as Salbutamol Sulfate) 2 Mg Oral Tablet” NCT05099107 ↗ “Ventolin® MDI * Ingredient: Salbutamol sulfate” NCT01076322 ↗ NCT02182700 ↗
Known as	Salbutamol sulphate	“As needed use of salbutamol sulphate aerosol (Ventolin) when exacerbation happens” NCT03842839 ↗ 5 “120 mcg salbutamol sulphate (equivalent to 100 mcg of the base)” NCT02182713 ↗ “Salbutamol sulphate (2.5 mg) + ipratropium bromide (0.5 mg)” NCT06825013 ↗ “VENTOLIN TABLETS 2MG (SALBUTAMOL SULPHATE)” NCT02405598 ↗ “Drug: Salbutamol sulphate” NCT01521572 ↗ NCT02182856 ↗
Known as	Salbutamol Sulphate BP	“Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)” NCT03333395 ↗
Known as	Salbutamol Sulphate Inhalation Aerosol (Ventolin)	“Salbutamol Sulphate Inhalation Aerosol (Ventolin®)” NCT03169504 ↗
Known as	Salbutamol Ventolin GSK	“"100 mcg Salbutamol Ventolin GSK" and "300 mcg Salbutamol Ventolin GSK"” NCT05884970 ↗
Known as	TBS-7	“The drug product albuterol sulfate DPI, TBS-7, is a single dose inhalation product of albuterol sulfate containing 240 ug albuterol sulphate (200 ug of albuterol)” NCT01252758 ↗
Known as	Ventilastin	“Salbutamol inhaler (200 µg per puff; a short acting β2-agonist; Ventilastin®).” NCT00633919 ↗
Known as	Ventolin	“cough medicine (such as codeine), bronchodilators (such as ventolin), expectorants (such as fluimucil) and so on are used to treat cough, shortness of breath, or other...” NCT06095258 ↗ 23 “Patients assigned to the active group will be treated with 0.15 mg/kg body weight (diluted in 3 mL 0.9% NaCl) nebulized salbutamol (Ventolin®, GlaxoSmithKline, Dublin, Ireland)...” NCT05527704 ↗ “Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)” NCT03333395 ↗ “The bronchodilator used in the study is the Salbutamol as Ventolin ® (GSK) suspension for inhalation as an aerosol at a dose of 100μg per puff.” NCT01470755 ↗ “Salbutamol will be delivered using a Babyhaler spacer device. Ventolin will be used, brandname for Salbutamol sulfate.” NCT04584034 ↗ “Nebulized salbutamol (Ventolin respiratory solution) 2.5 mg stat and once only with standard care” NCT02160548 ↗ “Salbutamol will be used to Group A patients: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose.” NCT03745261 ↗ “Ipratropium Bromide (Atrovent) & Albuterol (Ventolin) as Standard of Care” NCT04655170 ↗ “Albuterol sulfate inhalation aerosol (Ventolin®), 100 μg per actuation.” NCT07807007 ↗ “The drugs used by the children were zespira and ventolin.” NCT05930847 ↗ “Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp)” NCT00628758 ↗ Show 13 more sources
Known as	VENTOLIN (salbutamol)	“VENTOLIN (salbutamol)” NCT03924635 ↗ 1 “Ventolin (salbutamol)” NCT00876135 ↗
Known as	ventolin 2.5 Nebules 2.5mg/2.5 ml	“2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml, a bronchodilator)” NCT02159196 ↗
Known as	Ventolin MDI	“Ventolin® MDI * Ingredient: Salbutamol sulfate” NCT01076322 ↗
Known as	Ventoline	“The purpose of the project is to investigate whether the use of a WADA approved dose of salbutamol (albuterol/Ventoline) has a performance-enhancing effect on sprint...” NCT04402658 ↗ 1 NCT02103374 ↗
Known as	VentolinTM	“Salbutamol (VentolinTM) is a short acting beta agonist (SABA) which is used to treat wheezing, dyspnea and breathing difficulties caused by asthma and COPD.” NCT00911651 ↗
Known as	Volmax	“Volmax tb 4 mg/8 mg” NCT00628758 ↗
Known as	VoSpire ER	“The objective of this study was to investigate the bioequivalence of Mylan's albuterol sulfate extended-release 8 mg tablets to Pliva's VoSpire™ ER 8 mg tablets following a...” NCT00649779 ↗
Action	Inhibit	“reduces IL-12 expression” PMID 20837847 ↗ Sep 2010
Modality	Other / unclassified	“aerosolized β₂-agonist” PMID 21562125 ↗ Sep 2011
Route	Inhaled	“inhaled albuterol” NCT00000577 ↗